EARNINGS PRESENTATION Q4 2025 February 26, 2026 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like "will," "believe," "may ...

Core Insights - Integra LifeSciences Holdings Corporation reported a GAAP net loss of $(1.7) million for Q4 2025, a significant decline from a net income of $19.4 million in Q4 2024, reflecting operational challenges and a goodwill impairment charge [5][14] - The company generated total revenues of $434.9 million in Q4 2025, a decrease of 1.7% from the same quarter in 2024, with organic revenues down 2.5% [5][9] - For the full year 2025, total reported revenues were $1,635.2 million, an increase of 1.5% compared to 2024, but organic sales decreased by 0.7% [9][13] Fourth Quarter 2025 Financial Summary - Total reported revenues for Q4 2025 were $434.9 million, down 1.7% from Q4 2024, with organic revenues decreasing by 2.5% [5][9] - The company reported a GAAP net loss of $(1.7) million, or $(0.02) per diluted share, compared to a net income of $19.4 million, or $0.25 per diluted share in Q4 2024 [5][9] - Adjusted EBITDA for Q4 2025 was $104.2 million, slightly down from $104.9 million in Q4 2024, with an adjusted EBITDA margin of 24.0% [6][9] Full-Year 2025 Financial Summary - Total reported revenues for the full year 2025 were $1,635.2 million, an increase of 1.5% from 2024, while organic sales decreased by 0.7% [9][13] - The company reported a GAAP net loss of $(516.5) million, or $(6.74) per diluted share, primarily due to a $511 million goodwill impairment charge [14][15] - Adjusted net income for the full year 2025 was $171.4 million, or $2.23 per diluted share, compared to $196.9 million, or $2.56 per diluted share in 2024 [15][9] Segment Performance - Codman Specialty Surgical, which accounts for 75% of revenues, reported total revenues of $323.3 million in Q4 2025, an increase of 2.7% on a reported basis [10][9] - Tissue Technologies, representing 25% of revenues, saw total revenues decline by 12.8% in Q4 2025, reflecting challenges in the Wound Reconstruction segment [12][9] Cash Flow and Capital Allocation - Cash flows from operations totaled $11.8 million in Q4 2025, with capital expenditures of $17.2 million [7][9] - For the full year 2025, the company generated cash flow from operations of $50.4 million, with capital expenditures amounting to $81.4 million [16][9] 2026 Guidance - For the full year 2026, the company expects revenues to range from $1,662 million to $1,702 million, indicating reported growth of 1.6% to 4.1% and organic growth of 0.8% to 3.3% [17][18] - Adjusted earnings per diluted share for 2026 are projected to be between $2.30 and $2.40 [17][18]